One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Distilling the message: Irish plans for alcohol warning labels
doi : 10.1016/S2468-1253(23)00014-6
Volume 8, Issue 3, March 2023, Page 199
Treatment withdrawal in Crohn's disease: slowly becoming clearer
Ernst Fredericks
doi : 10.1016/S2468-1253(22)00405-8
Volume 8, Issue 3, March 2023, Pages 200-201
Addressing the risks of broad-scale H pylori eradication
M�rcis Leja
doi : 10.1016/S2468-1253(22)00426-5
Volume 8, Issue 3, March 2023, Pages 201-203
Accelerating point-of-care HCV viral load testing
Weiming Tang, Yusha Tao, *Joseph D Tucker
doi : 10.1016/S2468-1253(22)00381-8
Volume 8, Issue 3, March 2023, Pages 203-204
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia
Jason Grebely, Corey Markus, Louise M Causer, David Silk, Simon Comben, Andrew R Lloyd, Maria Martinez, Evan B Cunningham, Mim O’Flynn, Gregory J Dore, Susan Matthews, on behalf of the National Australian Hepatitis C Point-of-Care Testing Programâ€
doi : 10.1016/S2468-1253(22)00355-7
Volume 8, Issue 3, March 2023, Pages 204-207
Ethnicity, diversity, and inclusion in UK gastroenterology
Ajay M Verma, Neeraj Bhala
doi : 10.1016/S2468-1253(22)00425-3
Volume 8, Issue 3, March 2023, Pages 207-209
Trainee engagement in the Improving Quality in Liver Services accreditation programme
*James B Maurice, Ankur Srivastava, James Ferguson
doi : 10.1016/S2468-1253(22)00437-X
Volume 8, Issue 3, March 2023, Pages 209-210
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2022
doi : 10.1016/S2468-1253(23)00001-8
Volume 8, Issue 3, March 2023, Pages e1-e3
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer
Ruveyda Ayasun, *Ilyas Sahin
doi : 10.1016/S2468-1253(22)00402-2
Volume 8, Issue 3, March 2023, Page 211
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer – Authors' reply
Choong-kun Lee, *Hye Jin Choi
doi : 10.1016/S2468-1253(23)00006-7
Volume 8, Issue 3, March 2023, Pages 211-212
Research in Brief
Holly Baker
doi : 10.1016/S2468-1253(23)00015-8
Volume 8, Issue 3, March 2023, Page 213
Friends, Lovers, and the Big Terrible Thing
Hollie Sherwood-Martin
doi : 10.1016/S2468-1253(23)00016-X
Volume 8, Issue 3, March 2023, Page 214
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Edouard Louis, Matthieu Resche-Rigon*, David Laharie*, Jack Satsangi*, Nik Ding, Britta Siegmund, Geert D’Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel†, Erik Hertervig†, GETAID and the SPARE-Biocycle research group
doi : 10.1016/S2468-1253(22)00385-5
Volume 8, Issue 3, March 2023, Pages 215-227
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
Jyh-Ming Liou*†, Xiao-Tao Jiang*, Chieh-Chang Chen, Jiing-Chyuan Luo, Ming-Jong Bair, Po-Yueh Chen, Chu-Kuang Chou, Yu-Jen Fang, Mei-Jyh Chen, Chien-Chuan Chen, Ji-Yuh Lee, Tsung-Hua Yang, Chien-Chun Yu, Chia-Chi Kuo, Min-Chin Chiu, Chi-Yi Chen, Chia-Tung Shun, Wen-Hao Hu, Min-Horn Tsai, Yao-Chun Hsu, Cheng-Hao Tseng, Chi-Yang Chang, Jaw-Town Lin, Emad M El-Omar†, Ming-Shiang Wu†, for the Taiwan Gastrointestinal Disease and Helicobacter Consortium‡
doi : 10.1016/S2468-1253(22)00384-3
Volume 8, Issue 3, March 2023, Pages 228-241
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study
Manuel Luis RodrÃguez-Perálvarez*, Antonio Manuel Gómez-Orellana*, Avik Majumdar, Michael Bailey, Geoffrey W McCaughan, Paul Gow, Marta Guerrero, Rhiannon Taylor, David Guijo-Rubio, César Hervás-MartÃnez, Emmanuel A Tsochatzis
doi : 10.1016/S2468-1253(22)00354-5
Volume 8, Issue 3, March 2023, Pages 242-252
Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis
Adam Trickey, Emmanuel Fajardo, Daniel Alemu, Andreea Adelina Artenie, Philippa Easterbrook
doi : 10.1016/S2468-1253(22)00346-6
Volume 8, Issue 3, March 2023, Pages 253-270
Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition
Jochen Kammermeier*, Christopher A Lamb*, Kelsey D J Jones, Carl A Anderson, Emma L Baple, Chrissy Bolton, Helen Braggins, Tanya I Coulter, Kimberly C Gilmour, Vicki Gregory, Sophie Hambleton, David Hartley, A Barney Hawthorne, Sarah Hearn, Arian Laurence, Miles Parkes, Richard K Russell, R Alexander Speight, Simon Travis, David C Wilson, Holm H Uhlig
doi : 10.1016/S2468-1253(22)00337-5
Volume 8, Issue 3, March 2023, Pages 271-286
